• 1. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 2. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 3. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 4. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 5. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Fluorobenzenes
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides

Introduction to [(4-fluorophenyl)methyl]hydrazine hydrochloride (CAS No. 1059626-05-9)

[(4-fluorophenyl)methyl]hydrazine hydrochloride, identified by its CAS number 1059626-05-9, is a significant compound in the field of pharmaceutical chemistry. This compound has garnered attention due to its unique structural properties and potential applications in drug development. The presence of a 4-fluorophenyl group and a methylhydrazine moiety makes it a versatile intermediate for synthesizing various pharmacologically active molecules.

The chemical structure of [(4-fluorophenyl)methyl]hydrazine hydrochloride consists of a benzene ring substituted with a fluorine atom at the fourth position, connected to a methyl group, which in turn is linked to a hydrazine unit. This arrangement imparts specific electronic and steric properties that are exploited in medicinal chemistry. The hydrazine moiety, in particular, is known for its reactivity with carbonyl compounds, making it a valuable building block for constructing heterocyclic structures.

In recent years, there has been growing interest in the development of novel therapeutic agents that target various diseases, including cancer and neurological disorders. The structural features of [(4-fluorophenyl)methyl]hydrazine hydrochloride have made it a candidate for designing molecules with potential anticancer and neuroprotective properties. For instance, studies have shown that fluorinated aromatic compounds can enhance the bioavailability and metabolic stability of drug candidates, which is crucial for their clinical efficacy.

One of the most compelling aspects of [(4-fluorophenyl)methyl]hydrazine hydrochloride is its role as a precursor in the synthesis of more complex molecules. Researchers have utilized this compound to develop new analogs with improved pharmacokinetic profiles. The fluorine atom at the fourth position of the phenyl ring influences the electronic distribution, which can modulate the binding affinity of the resulting drug candidates to their biological targets. This has led to several innovative approaches in rational drug design.

The pharmaceutical industry has been particularly interested in exploring the potential of fluorinated hydrazines as scaffolds for drug discovery. For example, derivatives of [(4-fluorophenyl)methyl]hydrazine hydrochloride have been investigated for their ability to inhibit specific enzymes involved in cancer progression. Preliminary studies have demonstrated promising results in vitro, suggesting that these compounds may have therapeutic value when further optimized and tested in clinical trials.

The synthesis of [(4-fluorophenyl)methyl]hydrazine hydrochloride involves multi-step organic reactions that require careful optimization to ensure high yield and purity. The use of advanced synthetic techniques, such as palladium-catalyzed cross-coupling reactions, has facilitated the introduction of fluorine atoms into aromatic rings with greater precision. These methods have not only improved the efficiency of synthesis but also allowed for the creation of more diverse molecular libraries.

In conclusion, [(4-fluorophenyl)methyl]hydrazine hydrochloride (CAS No. 1059626-05-9) represents a significant advancement in pharmaceutical chemistry. Its unique structural features and reactivity make it a valuable tool for developing novel therapeutic agents. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in the discovery and development of next-generation drugs.

• 887595-39-3((3,5-difluorophenyl)methylhydrazine)
• 51421-16-0([(3-fluorophenyl)methyl]hydrazine)
• 699-05-8([(4-fluorophenyl)methyl]hydrazine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)